Aurobindo

Financial

Financial Results

FY 2005 - 2006

FY 2004 - 2005

FY 2003 - 2004

FY 2001 - 2002

FY 2000 - 2001

Financial Highlights

Dividend Record

Business Drivers

Investors

		Shareholding Pattern
		Share Performance
		Contact Person

Frequently Asked Questions

Unaudited Financial Results for the Quarter & Half year ended 30th September, 2002

(Rs. in Mio)

Three Months Ended

Six Months Ended

Year ended

Particulars

(Unaudited)

(Unaudited)

(Audited)

30.09.2002

30.09.2001

30.09.2002

30.09.2001

31.03.2002

Net Sales/Income from Operations

3048.4

2479.7

5520.8

4368.9

10377.2

Other Income

34.8

74.7

66.6

85.1

146.8

Total Income

3083.2

2554.4

5587.4

4454.0

10524.0

Expenditure

a.	(Increase) / Decrease in Stock in Trade

(120.5)

230.1

-(186.7)

148.2

209.3

b. Consumption of Raw Materials

2089.7

1504.8

3711.7

2723.0

6671.6

c. Staff Cost

57.3

62.3

116.2

117.7

251.7

d. Other Expenditure

630.0

446.5

1150.2

885.1

2020.9

Total expenditure

2656.5

2243.7

4791.4

3874.0

9153.6

Profit Before Depreciation, Interest& Tax

426.7

310.7

796.0

580.0

1370.4

Interest

92.1

99.4

220.1

209.5

423.9

Depreciation

43.3

40.6

82.6

77.1

158.1

Profit before extra-ordinary item& taxation
Add: Extra-ordinary item

291.3

170.7

493.3

293.4

788.4

100.0

Profit after extra ordinary item &before taxation

291.3

170.7

493.3

293.4

888.4

Provision for Taxation
a) Current Tax
b) Deferred Tax
c) Tax adjustments of previous years

63.0
23.1

27.1
-(1.8)

108.0
29.1

37.1
-(1.8)

153.7
37.9
11.7

Net Profit

205.2

145.4

356.2

258.1

685.1

Paid-up Equity Share Capital (Face Value Rs.10)

232.5

202.0

232.5

202.0

206.7

Reserves excluding Revaluation Reserves

--

--

--

--

3406.9

Basic Earnings per share(Rs.) (not annualised)

9.22

7.20

16.12

12.78

33.89

Dilluted Earnings per share(Rs.)

9.22

16.12

33.89

Aggregate of Non-promoter Shareholding

a. Number. of Shares

8914138

7638002

6978167

b. Percentage of Shareholding

38.34

37.81

33.76

Segmentwise Revenue Results and Capital Employed Under Clause 41 of the Listing Agreement

(Rs. in Mio)

Particulars	Three months ended 30.09.2002	Six months ended 30.09.2002	Year ended 31.03.2002 (Audited)
1. Segment Revenue
a . Bulk Drugs & Drug Intermediaries	3032.2	5455.4	10855.9
b. Formulation	153.3	296.5	1061.7
c. Research & Development	0	0	0
Total	3185.5	5751.9	11917.6
Less: Inter segment revenue	133.1	213.0	1433.0
Net Sales/Income from operation	3052.4	5538.9	10484.6
2. Segment Results Profit(+) / Loss(-) before tax and interest
a . Bulk Drugs & Drug Intermediaries	406.6	768.8	1444.6
b. Formulation	18.9	30.2	227.8
c. Research & Development	-(26.5)	-(45.4)	-(60.5)
Total	399.0	753.6	1611.9
Less: (I)Interest (Net)	69.1	189.9	392.6
(ii) Other un-allocable expenditure	38.6	70.4	330.9
net of unallocable income
Total Profit before tax	291.3	493.3	888.4
3. Capital Employed
a . Bulk Drugs	4899.0	4899.0	3870.9
b. Formulation	1266.9	1266.9	1180.0
c. Research & Development	207.0	207.0	173.9
Total	6372.9	6372.9	5224.8

1.	The above results were taken on record by the Board of Directors at their meeting held on October 31, 2002
2.	On 27th September, 2002, the Company allotted 10,50,000 equity shares of Rs.10/- each at a premium of Rs.216 on conversion of share warrants issued earlier under preferential issue.

For and on behalf of the Board

Sd/-

Place: Hyderabad

K.Nityananda Reddy

Date : 31.10.2002

Managing Director